PMID- 21155050
OWN - NLM
STAT- MEDLINE
DCOM- 20110503
LR  - 20211020
IS  - 1976-2437 (Electronic)
IS  - 0513-5796 (Print)
IS  - 0513-5796 (Linking)
VI  - 52
IP  - 1
DP  - 2011 Jan
TI  - Duration and magnitude of extracellular signal-regulated protein kinase 
      phosphorylation determine adipogenesis or osteogenesis in human bone 
      marrow-derived stem cells.
PG  - 165-72
LID - 10.3349/ymj.2011.52.1.165 [doi]
AB  - PURPOSE: Imbalances between osteogenic and adipogenic differentiation leads to 
      diseases such as osteoporosis. The aim of our study was to demonstrate the 
      differences in extracellular signal-regulated kinase (ERK) phosphorylation during 
      both adipogenesis and osteogenesis of human bone marrow-derived stem cells 
      (BMSCs). MATERIALS AND METHODS: Using troglitazone, GW9662 and U0126, we 
      investigated their role in hBMSC differentiation to adipogenic and osteogenic 
      fates. RESULTS: ERK1/2 inhibition by U0126 suppressed proliferator-activated 
      receptor (PPAR)gamma expression and lipid accumulation, while it decreased the mRNA 
      expression of adipogenic genes (lipoprotein lipase, PPARgamma, and adipocyte protein) 
      and osteogenic genes (type I collagen and osteopontin). ERK phosphorylation was 
      transient and decreased during adipogenesis, whereas it occurred steadily during 
      osteogenesis. Troglitazone, a PPARgamma agonist, induced adipogenesis by inhibiting 
      ERK phosphorylation even in an osteogenic medium, suggesting that ERK signaling 
      needs to be shut off in order to proceed with adipose cell commitment. Cell 
      proliferation was greatly increased in osteogenesis but was not changed during 
      adipogenesis, indicating that ERK might play different roles in cellular 
      proliferation and differentiation between the two committed cell types. 
      CONCLUSION: The duration and magnitude of ERK activation might be a crucial 
      factor for the balance between adipogenesis and osteogenesis in human bone 
      marrow-derived stem cells.
FAU - Jung, Ho Sun
AU  - Jung HS
AD  - Department of Orthopaedic Surgery, Yonsei University College of Medicine, Seoul, 
      Korea.
FAU - Kim, Yun Hee
AU  - Kim YH
FAU - Lee, Jin Woo
AU  - Lee JW
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Korea (South)
TA  - Yonsei Med J
JT  - Yonsei medical journal
JID - 0414003
RN  - 0 (2-chloro-5-nitrobenzanilide)
RN  - 0 (Anilides)
RN  - 0 (Butadienes)
RN  - 0 (Chromans)
RN  - 0 (Nitriles)
RN  - 0 (PPAR gamma)
RN  - 0 (Thiazolidinediones)
RN  - 0 (U 0126)
RN  - EC 2.7.11.24 (Extracellular Signal-Regulated MAP Kinases)
RN  - I66ZZ0ZN0E (Troglitazone)
SB  - IM
MH  - Adipogenesis/*drug effects/genetics
MH  - Adult
MH  - Anilides/pharmacology
MH  - Bone Marrow Cells/*cytology/drug effects/metabolism
MH  - Butadienes/pharmacology
MH  - Cell Differentiation/drug effects
MH  - Cells, Cultured
MH  - Chromans/pharmacology
MH  - Extracellular Signal-Regulated MAP Kinases/*metabolism
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Nitriles/pharmacology
MH  - Osteogenesis/*drug effects/genetics
MH  - PPAR gamma/agonists/antagonists & inhibitors
MH  - Phosphorylation/drug effects
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Stem Cells/*cytology/drug effects/*metabolism
MH  - Thiazolidinediones/pharmacology
MH  - Troglitazone
PMC - PMC3017693
COIS- The authors have no financial conflicts of interest.
EDAT- 2010/12/15 06:00
MHDA- 2011/05/04 06:00
PMCR- 2011/01/01
CRDT- 2010/12/15 06:00
PHST- 2010/12/15 06:00 [entrez]
PHST- 2010/12/15 06:00 [pubmed]
PHST- 2011/05/04 06:00 [medline]
PHST- 2011/01/01 00:00 [pmc-release]
AID - 201101165 [pii]
AID - 10.3349/ymj.2011.52.1.165 [doi]
PST - ppublish
SO  - Yonsei Med J. 2011 Jan;52(1):165-72. doi: 10.3349/ymj.2011.52.1.165.